Hannah Hodgkiss-Geere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hannah Hodgkiss-Geere has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Brendan M. Corcoran
3 shared publicationsDavid Bennett
3 shared publicationsDavid J. Argyle
3 shared publicationsElspeth Milne
3 shared publicationsSally A. Argyle
3 shared publications- Yolanda Martinez Pereira
Hospital for Small Animals, Royal (Dick) School of Veterinary Studies & the Roslin Institute, University of Edinburgh, Roslin, EH25 9RG, UK
3 shared publications
Latest Publications
- Open Access
- 6 December 2025
- Published by Wiley in Veterinary Record
- Vol. 198 (7) , e287-e292
Anti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy
Background: Evidence regarding the diagnostic utility of serum anti‐desmoglein‐2 (DSG2) autoantibodies for arrhythmogenic right ventricular cardiomyopathy (ARVC) in boxer dogs is conflicting. Methods: Prospective standardised evaluation of apparently healthy boxer dogs for ARVC was performed at three referral centres, including blood pressure measurement, electrocardiography, echocardiography, haematology, biochemistry (including cardiac troponin I) and 24‐hour Holter monitoring. Additional dogs with a diagnosis of ARVC were retrospectively recruited. ARVC disease status was defined using cut‐offs of 20 or less (unaffected) and more than 300 (affected) ventricular premature complexes of right ventricular origin in 24 hours. The residual serum samples were stored at ‒80°C for analysis for anti‐DSG2 autoantibodies using ELISA techniques. Results: Forty boxer dogs were enrolled (11 healthy controls, 10 with preclinical ARVC and 19 with clinical ARVC). Serum anti‐DSG2 autoantibodies were detected in all dogs, bar one healthy dog. DSG2 differed significantly between groups ( p = 0.031) and was significantly lower in dogs with preclinical versus clinical ARVC ( p = 0.025). Limitations: Some data were collected retrospectively, and some dogs were receiving antiarrhythmic therapy. Conclusion: Serum DSG2 autoantibodies can be present in boxer dogs with preclinical and clinical ARVC and apparently healthy controls.
- 6 December 2025
- Published by Wiley in Veterinary Record
- Vol. 198 (7) , e287-e292
Open AccessAnti‐desmoglein‐2 autoantibodies do not discriminate between UK boxer dogs with and without arrhythmogenic right ventricular cardiomyopathy
Background: Evidence regarding the diagnostic utility of serum anti‐desmoglein‐2 (DSG2) autoantibodies for arrhythmogenic right ventricular cardiomyopathy (ARVC) in boxer dogs is conflicting. Methods: Prospective standardised evaluation of apparently healthy boxer dogs for ARVC was performed at three referral centres, including blood pressure measurement, electrocardiography, echocardiography, haematology, biochemistry (including cardiac troponin I) and 24‐hour Holter monitoring. Additional dogs with a diagnosis of ARVC were retrospectively recruited. ARVC disease status was defined using cut‐offs of 20 or less (unaffected) and more than 300 (affected) ventricular premature complexes of right ventricular origin in 24 hours. The residual serum samples were stored at ‒80°C for analysis for anti‐DSG2 autoantibodies using ELISA techniques. Results: Forty boxer dogs were enrolled (11 healthy controls, 10 with preclinical ARVC and 19 with clinical ARVC). Serum anti‐DSG2 autoantibodies were detected in all dogs, bar one healthy dog. DSG2 differed significantly between groups ( p = 0.031) and was significantly lower in dogs with preclinical versus clinical ARVC ( p = 0.025). Limitations: Some data were collected retrospectively, and some dogs were receiving antiarrhythmic therapy. Conclusion: Serum DSG2 autoantibodies can be present in boxer dogs with preclinical and clinical ARVC and apparently healthy controls.
- Open Access
- 12 September 2023
- Published by Springer Nature in Research Square
Assessment of blood microRNA expression patterns by predictive classification algorithms can diagnose myxomatous mitral valve disease in dogs
Background: Myxomatous Mitral Valve Disease (MMVD) is a commonly presenting and progressive cardiac pathology in dogs, and early medical intervention can delay progression. Current cardiac biomarkers can be useful in advanced clinical MMVD cases, but are unreliable in pre-clinical disease.Objectives:Assessment of canine serum and plasma expression profiles of 15 miRNA markers as a method to accurately discriminate MMVD patients from healthy controls. Additionally, an assessment of the same method to discriminate pre-clinical (stage B1/B2) from clinical (stage C/D) MMVD patients.Animals:Client-owned dogs (n = 123) were recruited. Following sample exclusions (n=26), healthy controls (n=50) and MMVD cases (n=47) were analyzedMethods:Multicenter, cross-sectional, retrospective investigation. MicroRNA expression profiles were compared between dogs, and the performance of predictive modelling to distinguish healthy controls from MMVD patients, and pre-clinical from clinical MMVD patients was evaluated.Results:Analysis of miRNA expression patterns by predictive classification algorithms could differentiate healthy controls from dogs with MMVD (sensitivity 0.85; specificity 0.82; accuracy; 0.83). Discrimination of pre-clinical (n=29) from clinical (n=18) MMVD cases resulted in promising results (sensitivity 0.61; specificity 0.79; accuracy 0.73). The method also compared advantageously to current biomarkers in a limited population.Conclusions and clinical importance:The analysis of miRNA expression profiles by probabilistic predictive classification algorithms provides a useful diagnostic tool to distinguish healthy controls from MMVD cases (stage B1 to D). Discrimination between pre-clinical and clinical MMVD cases by the same method yielded promising results, which could be further enhanced with an increased study population.
- 12 September 2023
- Published by Springer Nature in Research Square
Open AccessAssessment of blood microRNA expression patterns by predictive classification algorithms can diagnose myxomatous mitral valve disease in dogs
Background: Myxomatous Mitral Valve Disease (MMVD) is a commonly presenting and progressive cardiac pathology in dogs, and early medical intervention can delay progression. Current cardiac biomarkers can be useful in advanced clinical MMVD cases, but are unreliable in pre-clinical disease.Objectives:Assessment of canine serum and plasma expression profiles of 15 miRNA markers as a method to accurately discriminate MMVD patients from healthy controls. Additionally, an assessment of the same method to discriminate pre-clinical (stage B1/B2) from clinical (stage C/D) MMVD patients.Animals:Client-owned dogs (n = 123) were recruited. Following sample exclusions (n=26), healthy controls (n=50) and MMVD cases (n=47) were analyzedMethods:Multicenter, cross-sectional, retrospective investigation. MicroRNA expression profiles were compared between dogs, and the performance of predictive modelling to distinguish healthy controls from MMVD patients, and pre-clinical from clinical MMVD patients was evaluated.Results:Analysis of miRNA expression patterns by predictive classification algorithms could differentiate healthy controls from dogs with MMVD (sensitivity 0.85; specificity 0.82; accuracy; 0.83). Discrimination of pre-clinical (n=29) from clinical (n=18) MMVD cases resulted in promising results (sensitivity 0.61; specificity 0.79; accuracy 0.73). The method also compared advantageously to current biomarkers in a limited population.Conclusions and clinical importance:The analysis of miRNA expression profiles by probabilistic predictive classification algorithms provides a useful diagnostic tool to distinguish healthy controls from MMVD cases (stage B1 to D). Discrimination between pre-clinical and clinical MMVD cases by the same method yielded promising results, which could be further enhanced with an increased study population.
- Open Access
- 29 September 2021
- Published by Wiley in Veterinary Clinical Pathology
- Vol. 50 (4) , 555-567
Comparison of effusion cell block and biopsy immunohistochemistry in mesothelial hyperplasia, mesothelioma, and carcinoma in dogs
Background: Determining the cause of effusions is challenging and might require a biopsy. Whether cell blocks from effusions are representative of biopsies requires investigation. A previously developed immunohistochemical panel aids in the differentiation of hyperplastic and neoplastic mesothelium in canine biopsies but has not been investigated in effusions.Objectives: The study aimed to assess cell blocks as an alternative to biopsies and determine whether immunohistochemistry helps distinguish hyperplastic mesothelium, mesothelioma, and carcinoma.Methods: Effusions and biopsies were collected from five dogs with mesothelial hyperplasia (group MH), six with mesothelioma (group M), and five with carcinoma (group C). Immunohistochemistry (IHC) for cytokeratin, vimentin, Wilm's tumor protein 1 (WT1), desmin, glucose transporter 1 (GLUT1), and insulin‐like growth factor II mRNA‐binding protein 3 (IMP3) was performed. Sections were scored for staining intensity and the percentage of positively stained cells.Results: In paired cell blocks and biopsies, vimentin and WT1 staining were positively correlated for intensity and the percentage of positive cells, although not all paired results were identical. The intensity of IMP3 staining in cell blocks was higher in group M than in group C (P = 0.012), and WT1 staining was higher in group MH than in group C (P = 0.020). For biopsies, the intensity of WT1 staining was higher in group MH than in group C (P = 0.031). In group C, WT1 was negative in all cell blocks and biopsies, and desmin was negative in four of five cases.Conclusions: IHC results for the cell blocks and biopsies were comparable for potentially useful markers, such as WT1, which helped discriminate between groups. IHC provided additional information, although results were not always definitive. Further studies on a larger population are required.
- 29 September 2021
- Published by Wiley in Veterinary Clinical Pathology
- Vol. 50 (4) , 555-567
Open AccessComparison of effusion cell block and biopsy immunohistochemistry in mesothelial hyperplasia, mesothelioma, and carcinoma in dogs
Background: Determining the cause of effusions is challenging and might require a biopsy. Whether cell blocks from effusions are representative of biopsies requires investigation. A previously developed immunohistochemical panel aids in the differentiation of hyperplastic and neoplastic mesothelium in canine biopsies but has not been investigated in effusions.Objectives: The study aimed to assess cell blocks as an alternative to biopsies and determine whether immunohistochemistry helps distinguish hyperplastic mesothelium, mesothelioma, and carcinoma.Methods: Effusions and biopsies were collected from five dogs with mesothelial hyperplasia (group MH), six with mesothelioma (group M), and five with carcinoma (group C). Immunohistochemistry (IHC) for cytokeratin, vimentin, Wilm's tumor protein 1 (WT1), desmin, glucose transporter 1 (GLUT1), and insulin‐like growth factor II mRNA‐binding protein 3 (IMP3) was performed. Sections were scored for staining intensity and the percentage of positively stained cells.Results: In paired cell blocks and biopsies, vimentin and WT1 staining were positively correlated for intensity and the percentage of positive cells, although not all paired results were identical. The intensity of IMP3 staining in cell blocks was higher in group M than in group C (P = 0.012), and WT1 staining was higher in group MH than in group C (P = 0.020). For biopsies, the intensity of WT1 staining was higher in group MH than in group C (P = 0.031). In group C, WT1 was negative in all cell blocks and biopsies, and desmin was negative in four of five cases.Conclusions: IHC results for the cell blocks and biopsies were comparable for potentially useful markers, such as WT1, which helped discriminate between groups. IHC provided additional information, although results were not always definitive. Further studies on a larger population are required.
- Open Access
- 6 September 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 13351
Cardiosphere-derived cells suppress allogeneic lymphocytes by production of PGE2 acting via the EP4 receptor
Cardiosphere-derived cells (CDCs) are a cardiac progenitor cell population, which have been shown to possess cardiac regenerative properties and can improve heart function in a variety of cardiac diseases. Studies in large animal models have predominantly focussed on using autologous cells for safety, however allogeneic cell banks would allow for a practical, cost-effective and efficient use in a clinical setting. The aim of this work was to determine the immunomodulatory status of these cells using CDCs and lymphocytes from 5 dogs. CDCs expressed MHC I but not MHC II molecules and in mixed lymphocyte reactions demonstrated a lack of lymphocyte proliferation in response to MHC-mismatched CDCs. Furthermore, MHC-mismatched CDCs suppressed lymphocyte proliferation and activation in response to Concanavalin A. Transwell experiments demonstrated that this was predominantly due to direct cell-cell contact in addition to soluble mediators whereby CDCs produced high levels of PGE2 under inflammatory conditions. This led to down-regulation of CD25 expression on lymphocytes via the EP4 receptor. Blocking prostaglandin synthesis restored both, proliferation and activation (measured via CD25 expression) of stimulated lymphocytes. We demonstrated for the first time in a large animal model that CDCs inhibit proliferation in allo-reactive lymphocytes and have potent immunosuppressive activity mediated via PGE2.
- 6 September 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 13351
Open AccessCardiosphere-derived cells suppress allogeneic lymphocytes by production of PGE2 acting via the EP4 receptor
Cardiosphere-derived cells (CDCs) are a cardiac progenitor cell population, which have been shown to possess cardiac regenerative properties and can improve heart function in a variety of cardiac diseases. Studies in large animal models have predominantly focussed on using autologous cells for safety, however allogeneic cell banks would allow for a practical, cost-effective and efficient use in a clinical setting. The aim of this work was to determine the immunomodulatory status of these cells using CDCs and lymphocytes from 5 dogs. CDCs expressed MHC I but not MHC II molecules and in mixed lymphocyte reactions demonstrated a lack of lymphocyte proliferation in response to MHC-mismatched CDCs. Furthermore, MHC-mismatched CDCs suppressed lymphocyte proliferation and activation in response to Concanavalin A. Transwell experiments demonstrated that this was predominantly due to direct cell-cell contact in addition to soluble mediators whereby CDCs produced high levels of PGE2 under inflammatory conditions. This led to down-regulation of CD25 expression on lymphocytes via the EP4 receptor. Blocking prostaglandin synthesis restored both, proliferation and activation (measured via CD25 expression) of stimulated lymphocytes. We demonstrated for the first time in a large animal model that CDCs inhibit proliferation in allo-reactive lymphocytes and have potent immunosuppressive activity mediated via PGE2.
- Open Access
- 2 April 2018
- Published by Wiley in Journal of Small Animal Practice
- Vol. 59 (5) , 261-271
Immunohistochemical differentiation of reactive from malignant mesothelium as a diagnostic aid in canine pericardial disease
Objectives: To develop a provisional immunohistochemistry panel for distinguishing reactive pericardium, atypical mesothelial proliferation and mesothelioma in dogs.Materials and Methods: Archived pericardial biopsies were subject to haematoxylin and eosin staining, immunohistochemistry for cytokeratin, vimentin, insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1 and desmin. Samples were scored for intensity and number of cells stained.Results: Ten biopsies of reactive mesothelium, 17 of atypical mesothelial proliferation, 26 of mesothelioma and five of normal pericardium were identified on the basis of haematoxylin and eosin staining. Cytokeratin and vimentin were expressed in all biopsies, confirming mesothelial origin. Normal pericardial samples had the lowest scores for insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1 and desmin. Mesothelioma and atypical proliferative samples were similar to each other, with higher scores for insulin‐like growth factor II mRNA‐binding protein 3 and glucose transporter 1 than the reactive samples. Desmin staining was variable. Insulin‐like growth factor II mRNA‐binding protein 3 was the best to distinguish between disease groups.Clinical Significance: An immunohistochemistry panel of cytokeratin, vimentin, insulin‐like growth factor II mRNA‐binding protein 3 and glucose transporter 1 could provide superior information compared with haematoxylin and eosin staining alone in the diagnosis of cases of mesothelial proliferation in canine pericardium, but further validation is warranted.
- 2 April 2018
- Published by Wiley in Journal of Small Animal Practice
- Vol. 59 (5) , 261-271
Open AccessImmunohistochemical differentiation of reactive from malignant mesothelium as a diagnostic aid in canine pericardial disease
Objectives: To develop a provisional immunohistochemistry panel for distinguishing reactive pericardium, atypical mesothelial proliferation and mesothelioma in dogs.Materials and Methods: Archived pericardial biopsies were subject to haematoxylin and eosin staining, immunohistochemistry for cytokeratin, vimentin, insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1 and desmin. Samples were scored for intensity and number of cells stained.Results: Ten biopsies of reactive mesothelium, 17 of atypical mesothelial proliferation, 26 of mesothelioma and five of normal pericardium were identified on the basis of haematoxylin and eosin staining. Cytokeratin and vimentin were expressed in all biopsies, confirming mesothelial origin. Normal pericardial samples had the lowest scores for insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1 and desmin. Mesothelioma and atypical proliferative samples were similar to each other, with higher scores for insulin‐like growth factor II mRNA‐binding protein 3 and glucose transporter 1 than the reactive samples. Desmin staining was variable. Insulin‐like growth factor II mRNA‐binding protein 3 was the best to distinguish between disease groups.Clinical Significance: An immunohistochemistry panel of cytokeratin, vimentin, insulin‐like growth factor II mRNA‐binding protein 3 and glucose transporter 1 could provide superior information compared with haematoxylin and eosin staining alone in the diagnosis of cases of mesothelial proliferation in canine pericardium, but further validation is warranted.
- 1 January 2018
- Published by Wiley in Cytometry Part A
- Vol. 93A (1) , 115-124
Cryopreservation of canine cardiosphere-derived cells: Implications for clinical application
The clinical application of cardiosphere-derived cells (CDCs) to treat cardiac disease has gained increasing interest over the past decade. Recent clinical trials confirm their regenerative capabilities, although much remains to be elucidated about their basic biology. To develop this new treatment modality, in a cost effective and standardized workflow, necessitates the creation of cryopreserved cell lines to facilitate access for cardiac patients requiring urgent therapy. Cryopreservation may however lead to alterations in cell behavior and potency. The aim of this study was to investigate the effect of cryopreservation on canine CDCs. CDCs and mesenchymal stem cells (MSCs) isolated from five dogs were characterized. CDCs demonstrated a population doubling time that was unchanged by cryopreservation (fresh vs. cryopreserved; 57.13 +/- 5.27 h vs. 48.94 +/- 9.55 h, P=0.71). This was slower than for MSCs (30.46 h, P<0.05). The ability to form clones, self-renew, and commit to multiple lineages was unaffected by cryopreservation. Cryopreserved CDCs formed larger cardiospheres compared to fresh cells (P<0.0001). Fresh CDCs showed a high proportion of CD105(+) (89.0%+/- 4.98) and CD44(+) (99.68%+/- 0.13) cells with varying proportions of CD90(+) (23.36%+/- 9.78), CD34(+) (7.18%+/- 4.03) and c-Kit(+) (13.17%+/- 8.67) cells. CD45(+) (0.015%+/- 0.005) and CD29(+) (2.92%+/- 2.46) populations were negligible. Increasing passage number of fresh CDCs correlated with an increase in the proportion of CD34(+) and a decrease in CD90(+) cells (P=0.003 and 0.03, respectively). Cryopreserved CDCs displayed increased CD34(+) (P<0.001) and decreased CD90(+) cells (P=0.042) when compared to fresh cells. Overall, our study shows that cryopreservation of canine CDCs is feasible without altering their stem characteristics, thereby facilitating their utilization for clinical trials. (c) 2017 International Society for Advancement of Cytometry
- 1 January 2018
- Published by Wiley in Cytometry Part A
- Vol. 93A (1) , 115-124
Cryopreservation of canine cardiosphere-derived cells: Implications for clinical application
The clinical application of cardiosphere-derived cells (CDCs) to treat cardiac disease has gained increasing interest over the past decade. Recent clinical trials confirm their regenerative capabilities, although much remains to be elucidated about their basic biology. To develop this new treatment modality, in a cost effective and standardized workflow, necessitates the creation of cryopreserved cell lines to facilitate access for cardiac patients requiring urgent therapy. Cryopreservation may however lead to alterations in cell behavior and potency. The aim of this study was to investigate the effect of cryopreservation on canine CDCs. CDCs and mesenchymal stem cells (MSCs) isolated from five dogs were characterized. CDCs demonstrated a population doubling time that was unchanged by cryopreservation (fresh vs. cryopreserved; 57.13 +/- 5.27 h vs. 48.94 +/- 9.55 h, P=0.71). This was slower than for MSCs (30.46 h, P<0.05). The ability to form clones, self-renew, and commit to multiple lineages was unaffected by cryopreservation. Cryopreserved CDCs formed larger cardiospheres compared to fresh cells (P<0.0001). Fresh CDCs showed a high proportion of CD105(+) (89.0%+/- 4.98) and CD44(+) (99.68%+/- 0.13) cells with varying proportions of CD90(+) (23.36%+/- 9.78), CD34(+) (7.18%+/- 4.03) and c-Kit(+) (13.17%+/- 8.67) cells. CD45(+) (0.015%+/- 0.005) and CD29(+) (2.92%+/- 2.46) populations were negligible. Increasing passage number of fresh CDCs correlated with an increase in the proportion of CD34(+) and a decrease in CD90(+) cells (P=0.003 and 0.03, respectively). Cryopreserved CDCs displayed increased CD34(+) (P<0.001) and decreased CD90(+) cells (P=0.042) when compared to fresh cells. Overall, our study shows that cryopreservation of canine CDCs is feasible without altering their stem characteristics, thereby facilitating their utilization for clinical trials. (c) 2017 International Society for Advancement of Cytometry
- Open Access
- 8 August 2017
- Published by Springer Nature in Veterinary Research Communications
- Vol. 41 (4) , 249-256
Vasovagal tonus index (VVTI) as an indirect assessment of remission status in canine multicentric lymphoma undergoing multi-drug chemotherapy
Vasovagal tonus index (VVTI) is an indirect measure of heart rate variability and may serve as a marker of disease severity. Higher heart rate variability has predicted lower tumour burden and improved survival in humans with various tumour types. The purpose of this pilot study was to evaluate VVTI as a biomarker of remission status in canine lymphoma. The primary hypothesis was that VVTI would be increased in dogs in remission compared to dogs out of remission. Twenty-seven dogs were prospectively enrolled if they had a diagnosis of intermediate to high-grade lymphoma and underwent multidrug chemotherapy. Serial electrocardiogram data were collected under standard conditions and relationships between VVTI, remission status and other clinical variables were evaluated. VVTI from dogs in remission (partial or complete) did not differ from dogs with fulminant lymphoma (naive or at time of relapse). Dogs in partial remission had higher VVTI than dogs in complete remission (p = 0.021). Higher baseline VVTI was associated with higher subsequent scores (p < 0.001). VVTI also correlated with anxiety level (p = 0.03). Based on this pilot study, VVTI did not hold any obvious promise as a useful clinical biomarker of remission status. Further investigation may better elucidate the clinical and prognostic utility of VVTI in dogs with lymphoma.
- 8 August 2017
- Published by Springer Nature in Veterinary Research Communications
- Vol. 41 (4) , 249-256
Open AccessVasovagal tonus index (VVTI) as an indirect assessment of remission status in canine multicentric lymphoma undergoing multi-drug chemotherapy
Vasovagal tonus index (VVTI) is an indirect measure of heart rate variability and may serve as a marker of disease severity. Higher heart rate variability has predicted lower tumour burden and improved survival in humans with various tumour types. The purpose of this pilot study was to evaluate VVTI as a biomarker of remission status in canine lymphoma. The primary hypothesis was that VVTI would be increased in dogs in remission compared to dogs out of remission. Twenty-seven dogs were prospectively enrolled if they had a diagnosis of intermediate to high-grade lymphoma and underwent multidrug chemotherapy. Serial electrocardiogram data were collected under standard conditions and relationships between VVTI, remission status and other clinical variables were evaluated. VVTI from dogs in remission (partial or complete) did not differ from dogs with fulminant lymphoma (naive or at time of relapse). Dogs in partial remission had higher VVTI than dogs in complete remission (p = 0.021). Higher baseline VVTI was associated with higher subsequent scores (p < 0.001). VVTI also correlated with anxiety level (p = 0.03). Based on this pilot study, VVTI did not hold any obvious promise as a useful clinical biomarker of remission status. Further investigation may better elucidate the clinical and prognostic utility of VVTI in dogs with lymphoma.
- 1 April 2017
- Published by British Small Animal Veterinary Association
- p. 470
Tissue Doppler imaging at the mitral annulus for prediction of new-onset atrial fibrillation
BSAVA library: We promote excellence in small animal practice through education and science. Online Library contains Manuals, Guides, Formularies and other content from the BSAVA.
- 1 April 2017
- Published by British Small Animal Veterinary Association
- p. 470
Tissue Doppler imaging at the mitral annulus for prediction of new-onset atrial fibrillation
BSAVA library: We promote excellence in small animal practice through education and science. Online Library contains Manuals, Guides, Formularies and other content from the BSAVA.
- Open Access
- 1 May 2016
- Published by Wiley in Veterinary Record Case Reports
- Vol. 4 (1) , e000316
Concurrent physitis and portosystemic shunts in three dogs
Hepatic disease is a known risk factor for the development of bone infection in human beings. Three dogs with portosystemic shunting and concurrent physitis are presented here and an association is postulated between both disease processes. Portosystemic shunting may be a risk factor for the development of physitis in dogs. Skeletal structures should not be overlooked when reviewing diagnostic imaging studies of dogs with portosystemic shunts. Skeletal infections should be considered as a differential diagnosis in dogs with liver disease and concurrent skeletal abnormalities.
- 1 May 2016
- Published by Wiley in Veterinary Record Case Reports
- Vol. 4 (1) , e000316
Open AccessConcurrent physitis and portosystemic shunts in three dogs
Hepatic disease is a known risk factor for the development of bone infection in human beings. Three dogs with portosystemic shunting and concurrent physitis are presented here and an association is postulated between both disease processes. Portosystemic shunting may be a risk factor for the development of physitis in dogs. Skeletal structures should not be overlooked when reviewing diagnostic imaging studies of dogs with portosystemic shunts. Skeletal infections should be considered as a differential diagnosis in dogs with liver disease and concurrent skeletal abnormalities.
- 25 June 2014
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 17 (4) , 381-386
Pericardial cyst in a 2-year-old Maine Coon cat following peritoneopericardial diaphragmatic hernia repair
A pericardial cyst developed in a 2-year-old male neutered Maine Coon cat following surgery for an incidentally diagnosed congenital peritoneopericardial diaphragmatic hernia. The cyst caused no clinical signs in the cat, although clinical findings included positional right-sided cardiac tamponade and compression of thoracic structures, associated with a cardiac arrhythmia and axis deviation on electrocardiography. Extensive assessment of the cyst included radiography, echocardiography, computed tomography, exploratory thoracotomy, electrocardiography, histopathology and fluid analysis. Surgical removal of the cyst was curative, and the arrhythmia and axis deviation resolved. This report details case management from initial diagnosis to long-term follow-up, adding to the limited body of literature available on feline pericardial cysts. This is also the first report to associate cardiac arrhythmia with a pericardial cyst.
- 25 June 2014
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 17 (4) , 381-386
Pericardial cyst in a 2-year-old Maine Coon cat following peritoneopericardial diaphragmatic hernia repair
A pericardial cyst developed in a 2-year-old male neutered Maine Coon cat following surgery for an incidentally diagnosed congenital peritoneopericardial diaphragmatic hernia. The cyst caused no clinical signs in the cat, although clinical findings included positional right-sided cardiac tamponade and compression of thoracic structures, associated with a cardiac arrhythmia and axis deviation on electrocardiography. Extensive assessment of the cyst included radiography, echocardiography, computed tomography, exploratory thoracotomy, electrocardiography, histopathology and fluid analysis. Surgical removal of the cyst was curative, and the arrhythmia and axis deviation resolved. This report details case management from initial diagnosis to long-term follow-up, adding to the limited body of literature available on feline pericardial cysts. This is also the first report to associate cardiac arrhythmia with a pericardial cyst.